IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1093/brain/aww113</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002718">http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002718</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation

Lior Mayo,1,2 Andre Pires Da Cunha,1 Asaf Madi,3 Vanessa Beynon,1 Zhiping Yang,4 Jorge I. Alvarez,5,6 Alexandre Prat,5 Raymond A. Sobel,7 Lester Kobzik,4 Hans Lassmann,8 Francisco J. Quintana1 and Howard L. Weiner1

See Winger and Zamvil (doi:10.1093/brain/aww121) for a scientific commentary on this article.

The innate immune system plays a central role in the chronic central nervous system inflammation that drives neurological disability in progressive forms of multiple sclerosis, for which there are no effective treatments. The mucosal immune system is a unique tolerogenic organ that provides a physiological approach for the induction of regulatory T cells. Here we report that nasal administration of CD3-specific antibody ameliorates disease in a progressive animal model of multiple sclerosis. This effect is IL-10-dependent and is mediated by the induction of regulatory T cells that share a similar transcriptional profile to Tr1 regulatory cells and that suppress the astrocyte inflammatory transcriptional program. Treatment results in an attenuated inflammatory milieu in the central nervous system, decreased microglia activation, reduced recruitment of peripheral monocytes, stabilization of the blood–brain barrier and less neurodegeneration. These findings suggest a new therapeutic approach for the treatment of progressive forms of multiple sclerosis and potentially other types of chronic central nervous system inflammation.

1 Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
2 Cell Research and Immunology Department, Sagol School of Neuroscience, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 699788, Israel
3 Evergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA
4 Environmental Health Department, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
5 Neuroimmunology Research Lab, CRCHUM, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
6 Pathobiology Department, University of Pennsylvania, Philadelphia, PA 19104, USA
7 Stanford University School of Medicine, Stanford, USA
8 Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A-1090 Wien, Austria

Correspondence to: Howard L. Weiner,
Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital,
Harvard Medical School,
77 Avenue Louis Pasteur,
HIM 730,
Boston, MA 02115,
USA
E-mail: hweiner@rics.bwh.harvard.edu

Keywords: astrocyte; neuroinflammation; multiple sclerosis; T-lymphocytes; interleukin 10

Abbreviations: EAE = experimental autoimmune encephalomyelitis; GFP = green fluorescent protein; LAP = latency-associated peptide; mAb = monoclonal antibody; Tr1 = type 1 regulatory
Introduction

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the CNS. Approximately 85% of patients with multiple sclerosis initially exhibit a relapsing-remitting clinical course of the disease in which autoimmune attacks lead to impaired neurological function that are followed by periods of recovery. Many patients subsequently develop secondary progressive multiple sclerosis, characterized by the progressive and irreversible accumulation of neurological disability (Compston and Coles, 2008; Lassmann et al., 2012; Nylander and Hafler, 2012). Although the pathophysiologic processes underlying these two phases of the disease and what determines the transition from one phase to the other are not well understood, recent studies suggest that the progressive phase is linked to a change in the nature of the CNS inflammation that is primarily driven by local innate immune responses (Anderson et al., 2007; Basso et al., 2008; Weiner, 2008; Farez et al., 2009; Mayo et al., 2012, 2014). Current FDA-approved multiple sclerosis therapies act by modulating or suppressing the peripheral immune response and have limited if any effect on progressive forms of multiple sclerosis. Furthermore, many of these therapies are associated with serious side effects (Wingerchuk and Carter, 2014). Thus, identifying novel therapies that address the chronic CNS inflammation associated with progressive forms of multiple sclerosis remains a major unmet need.

Interleukin 10 (IL-10) is a pleiotropic cytokine that has a broad spectrum of anti-inflammatory properties (Moore et al., 2001). Decreased IL-10 levels have been associated with multiple sclerosis severity and with the progressive stage of the disease (van Boxel-Dezaire et al., 1999; Peterit et al., 2003; Soldan et al., 2004) and numerous studies have demonstrated the importance of IL-10 in acute experimental autoimmune encephalomyelitis (EAE) by targeting the peripheral immune response (Moore et al., 2001). Type-I regulatory T cells (Tr1 cells) have emerged as an important subset of CD4+ T cells that limits excessive inflammatory responses (Roncarolo et al., 2006; Allan et al., 2008). The anti-inflammatory properties of Tr1 cells mainly rely on the secretion of IL-10, which suppresses tissue inflammation and autoimmunity. Accordingly, we and others have shown that treatments that induce Tr1-like cells, such as IL27, or dexamethasone and vitamin D3, were beneficial in the treatment of acute EAE (Barrat et al., 2002; Fitzgerald et al., 2007; Apetoh et al., 2010). Of note, lower levels of vitamin D have been associated with increased disease severity in multiple sclerosis, and a recent study indicated that vitamin D supplementation in vitro could partly restore the defective CD46 triggered Tr1 response of patients with relapsing remitting multiple sclerosis (Astier et al., 2007; Kickler et al., 2012; Kleineveld and Hafler, 2014). However, the therapeutic potential of the Tr1/IL-10 axis in progressive disease is unknown, as are its effects on the CNS innate immune system.

A major challenge of immunotherapy is the induction of regulatory T cells, such as Tr1 cells, in a non-toxic and physiological fashion. It is now well-established that stimulation of the mucosal immune system has the unique physiologic property of inducing regulatory T cells (Weiner et al., 2011) and is an attractive, clinically applicable approach that lacks apparent toxicity. We and others have demonstrated that nasal administration of protein antigens or of CD3-specific monoclonal antibody (mAb) is an efficient method for the induction of IL-10 producing CD4+ cells that suppresses inflammatory models of disease (Frenkel et al., 2003; Wu et al., 2008, 2010, 2011; Weiner et al., 2011). Here we report that nasal anti-CD3 induces IL-10+ LAP+ (latency-associated peptide) Tr1-like T cells that suppress the progressive model of multiple sclerosis in an IL-10-dependent manner by attenuating CNS innate immunity including astrocytes and microglia. These findings identify a new immunological approach for the treatment of progressive forms of multiple sclerosis and potentially other types of chronic CNS inflammation.

Materials and methods

Animals

NOD/ShiLtJ (NOD, non-obese diabetic), C57BL/6J, and IL-10-GFP knock-in mice (B6.129S6-Il10tm1Flv/J) were from The Jackson Laboratory. Wild-type or IL-10 green fluorescent protein (GFP)-bearing F1 heterozygote mice were generated by breeding NOD mice and wild-type or relevant GFP knock-in C57BL/6 mice (B6NODF1). All animals were kept in a pathogen-free facility at the Harvard Institutes of Medicine. All experiments were carried out in accordance with guidelines prescribed by the Institutional Animal Care and Use Committee of Harvard Medical School.

EAE induction and treatment

EAE was induced by immunization female mice with myelin oligodendrocyte glycoprotein peptide (MOG35-55) emulsified in complete Freund's adjuvant (Difco Laboratories) at a dose of 100 μg (F1 mice and C57BL/6 J) or 150 μg (NOD mice) per mouse, followed by the administration of pertussis toxin (150 ng per mouse; List biological laboratories, Inc.) on Days 0 and 2 as described (Farez et al., 2009). Clinical signs of EAE were assessed according to the following score: 0, no signs of disease; 1, loss of tone in the tail; 2, hind limb paresis; 3, hind limb paralysis; 4, tetraplegia; 5, moribund. For the induction on nasal tolerance, mice were nasally treated with a daily dose of 1 μg/mouse hamster IgG CD3-specific antibody (clone 145-2C11, BioXCell), or hamster IgG control antibody (BioXCell) dissolved in phosphate-buffered saline (PBS). For some experiments, mice were given 0.5 mg of monoclonal anti-IL-10R blocking antibody (clone 1B1.3A, Bioxcell) or appropriate isotype control (Clone: HRPN, Bioxcell), by intraperitoneal
injection at the onset of the progressive phase, and henceforth every fourth day until experimental end point.

**Mouse model of pneumococcal pneumonia**

Primary pneumococcal pneumonia was modelled as previously reported (Arredouani et al., 2004; Yang et al., 2015). Pneumonia was induced by intranasal instillation of \(~10^3\) colony-forming units (CFU) of *Streptococcus pneumoniae* type 3 into mice under anaesthesia with ketamine (120 mg/kg intraperitoneally) plus xylazine (16 mg/kg intraperitoneally); actual CFU administered were quantitated by CFU assay and used subsequently to calculate per cent clearance. Bronchoalveolar lavage was performed at 24 h of lung inflammation and lung inflammation and bacterial clearance were analysed as previously described (Arredouani et al., 2004; Yang et al., 2015).

**Rotarod assay**

The rotarod was set to accelerate from a speed of 4 to 40 rotations per min in a 300-s time trial. Each mouse was given an exposure trial to familiarize the animal with the task, and this initial trial was not included for data analysis. Each animal was then given two trials and the times at which mice could no longer successfully manage or remain on the rotarod were averaged and analysed for differences between treatment groups.

**MOG<sub>35-55</sub> tetramer staining**

To identify MOG<sub>35-55</sub> specific T cells, single-cell suspensions from spleen were prepared and stained with MOG<sub>35-55</sub>-tetramer-PE (MBL) according to manufacturer's instructions. In brief, the cells were stained for 30 min at 4°C, and incubated for additional 30 min with FITC anti-mouse CD3 (145-2C11), APC anti-mouse CD4 ( GK1.5) and Brilliant Violet 421<sup>™</sup> anti-mouse LAP (TW7-16B4) (all from Biolegend). Cells were analysed using LSR-II FACS analyser in the presence of 7-AAD for the exclusion of non-viable cells. ‘Fluorescence minus one’ (FMO) controls were used to set the gate.

**Near-infrared fluorescence in vivo imaging**

The IVIS Lumina III In Vivo Imaging System (PerkinElmer) was used to perform *in vivo* near infrared (NIR) imaging. Images were acquired with a 710 nm excitation filter and a Cy5.5 emission filter. Living Image 4.2 software (PerkinElmer) was used for data analysis. Mice were treated nasally with DyLight 755<sup>™</sup>-conjugated anti-CD3 mAb (clone 145-2C11, Novus Biologicals), and 5 h later the *in vivo* biodistribution of the mAb determined.

**Adoptive transfer**

To test the *in vivo* regulatory function of the nasally induced T cells we transferred freshly isolated whole CD4<sup>+</sup> or CD4<sup>+</sup> T cells depleted of LAP<sup>+</sup> cells from anti-CD3 or isotype control-treated NOD mice during the progressive phase of EAE (Day 60) were transferred to a new cohort of NOD mice at the onset of the progressive phase. Each recipient received 4 × 10<sup>6</sup>T cells intravenously.

**Immunohistochemistry**

Animals were perfused with PBS, followed by 4% paraformaldehyde in 0.1 M PBS, and tissue was processed and stained as previously described (Mayo et al., 2014). For immunofluorescence staining, sections were stained with GFAP (mouse, 1:300, BD Biosciences), GFP (chicken, 1:500, Abcam), followed by an appropriate fluorophore-conjugated goat secondary antibodies (1:1000; Abcam). Six animals per group were used. Images were taken using a LSM 710 confocal microscope (Carl Zeiss). Paraffin embedded sections were stained with haematoxylin and eosin, Luxol Fast blue for myelin, Bielschowsky silver impregnation for axons, or incubated with primary antibodies against GFAP (rabbit, 1:3000, neo-marker), AQP4 (rabbit, 1:250, Sigma), amyloid precursor protein (APP, 1:1000; Milipore), mouse IgG (1:1500, Jackson Research), and fibrin (1:1000, USBIO), followed by biotinylated secondary antibodies (Amersham or Jackson Immuno Research) and bound antibodies, were visualized by diaminobenzidine as chromogen.

**In vivo blood–brain barrier permeability**

Naïve and isotype control or anti-CD3 treated NOD mice were injected with 0.1 ml of 70 kDa FITC-conjugated dextran (1 mg/ml) into the tail vein, and 600 μl of Evans blue 1%, as previously described (Alvarez et al., 2011) with minor modifications. Mice were anaesthetized 2 h post-injection, perfused with PBS, and Dextran-FITC, and Evans blue extravasation to the spinal cord visualized using a LSM 710 confocal microscope (Carl Zeiss).

**Fluorescence-activated cell sorting of astrocytes, microglia and monocytes**

Isolated CNS cells were purified by cell sorting using FACS Aria I (BD Bioscience) as previously described (Mayo et al., 2014). Microglia were sorted as CD11b<sup>+</sup> cells with low CD45<sup>+</sup> expression and low Ly6C<sup>+</sup>(Prinz et al., 2011). T cells were sorted as CD3<sup>+</sup> CD4<sup>+</sup> cells. Astrocytes were isolated following the depletion of microglia, monocytes, oligodendrocytes, and lymphocytes [T cells, B cells, and natural killer (NK) cells].

**Microarray analysis**

RNA was processed, amplified, labelled, and hybridized to Affymetrix GeneChip<sup>®</sup> MoGene 1.0 ST microarrays (Affymetrix) by the Dana-Farber Cancer Institute Microarray facility. Robust multi-array average (RMA) and quantile normalization were applied for background correction and normalization using the ExpressionFileCreator module of GenePatterns. Differentially expressed genes were identified using the Marker selection module of GeneE (GENE-E version 1941).
3.0.224), based on statistical differences in signal-to-noise ratio, following correction for multiple hypotheses testing by computing both the false discovery rate (FDR). Differentially expressed genes were identified as having an FDR < 0.2. Significance Analysis of Microarrays and Gene Set Enrichment Analysis (GSEA) were performed (Subramanian et al., 2005).

**nCounter gene expression**

Total RNA (50–100 ng) was hybridized with reporter and capture probes for nCounter Gene Expression code sets (Mouse Immunology panel, or a custom made astrocyte-oriented probe set; Mayo et al., 2014), according to manufacturer’s instructions analysed by use of the Expander 6.05 platform (Ulitsky et al., 2010).

**Quantitative polymerase chain reaction**

RNA was extracted with RNeasy® columns (Qiagen), or TRIzol® (Invitrogen), cDNA was prepared and used for quantitative PCR and the results were normalized to Gapdh (mice) or ACTIN (human). All primers and probes were from Applied Biosystems, Aqp4 (Mm00484688_m1), Ccl2 (Mm013002_2221_m1), Cd40 (Mm00441891_m1), Csf2 (Mm01290062_m1), Cxcl10 (Mm00452353_m1), Foxp3 (Mm00475162_m1), Gapdh (Mm00442991_m1), Mmp9 (Mm00443260_g1), Spp1 (Mm00436767_m1), Tgfb1 (Mm00445235_m1), Il6 (Mm00441891_m1), Il10 (Mm00439618_m1), Tnf (Mm00445235_m1), H2-Aa (Mm00439211_m1), Il4 (Mm00445228_m1), Il14 (Mm00445259_m1), Il6 (Mm00446190_m1), Nos2 (Mm00440502_m1), Spp1 (Mm00436767_m1), Tbx21 (Mm00450960_m1), Tgfb1 (Mm01178820_m1), Tlr2 (Mm00442346_m1), Tnf (Mm00443260_g1), Vegfa (Mm01281449_m1), Irf7 (Mm00516793_g1), Gata3 (Mm00484683_m1), ACTB (Hs01872448_s1), IL10RA (Hs00155485_m1). Invitrogen). Cells were stimulated with 1 μg/ml of soluble anti-CD3 in the presence of mitomycin-treated antigen-presenting cells. Proliferation was assessed 48 h later by flow cytometry based on the dilution of the CellTrace™ Violet dye on responder cells. In some experiments, monoclonal anti-IL-10R blocking antibody (clone 1B1.3A, Bioxcell) or appropriate isotype control (clone: HRPN, Bioxcell) were added (50 μg/ml) directly to the co-culture.

**T cell differentiation in vitro**

Naive CD4+CD62Lhigh CD44low T cells were stimulated for 60 h using plate-bound antibody to CD3 (2 μg/ml) (145-2C11, Biolegend) and soluble antibody to CD28 (1 μg/ml) (PV-1, BioXcell) in the presence of recombinant cytokines. T cells were polarized with recombinant TGF-β1 (3 ng/ml, R&D) for FOXP3+ Treg, recombinant IL27 (30 ng/ml, ebioscience) or recombinant IL27 and TGF-β1 for Tr1 cells, and Tho were maintained with recombinant mouse IL2 (10 ng/ml).

**Mouse primary microglia**

Mouse primary microglia were prepared as described (Saura et al., 2003; Mayo et al., 2014) with minor modifications. Microglia purity were >98%, as determined by staining with fluorescein-conjugated Griffonia simplicifolia isolecitin B4 (IB4) (Vector Laboratories) or PE-conjugated CD11b antibody (data not shown).

**Mouse primary astrocytes**

Mixed glia were prepared as described (Saura et al., 2003; Mayo et al., 2014), and cultured until confluent (Day 7–10). The cells were then incubated with 0.02 mg/ml of clodronate encapsulated liposomes (Clodrosome) (Encapsula NanoSciences LLC) for 2–3 days, washed, and the astrocyte monolayer separated using the mild trypsinization procedure, and plated. Cells were >99% astrocytes, as determined by staining with GFAP or GLAST, with <1% contamination of CD11b+ microglia cells (data not shown).

**In vivo astrocyte-specific knock-down with short hairpin RNA lentivirus**

pLenti-GFP-EGFP-mir30-short hairpin (sh)RNA harbouring shRNA sequences against Il10ra, or a non-targeting shRNA were cloned using the pLenti-pGFP-EGFP-mir30-shRNA vector (Yan et al., 2012) or the pLenti-pCD11b-EGFP-mir30-shRNA (Ding et al., 2015) as a backbone, by replacing the shRNA for Act1 with the abovementioned in vitro validated shRNA sequences (Il10ra : 5' cggCGCCTTGTGGAATTTCC GTAATTTACCTGTTTAATTCGAGGATGCACTTT-3') and a non-targeting shRNA. Lentivirus particles were then generated as described (Mayo et al., 2014). NOD EAE mice, 35 days after immunization (progressive phase), were anaesthetized with isoflurane and placed in a Kopf Stereotaxic Alignment System. Using a Hamilton syringe, 107 IU/mouse of shIL10ra, or shControl (non-targeting) virus were injected 0.5 mm posterior to the bregma, ±1.0 mm lateral to it and 2.2 mm below the skull surface.
Monocyte migration assay

Splenic Ly6Chigh monocytes were freshly sorted (CD11b+F4-80+SSC<low>Ly6Chigh), and their ability to migrate towards CCL2 (50 ng/ml, peprotech), astrocyte-conditioned media, or vehicle control (PBS), was determined as previously described (Mayo et al., 2014).

Multiple sclerosis tissue

Brain tissue was obtained from patients with multiple sclerosis with clinically diagnosed and neuropathologically confirmed multiple sclerosis, or healthy controls were immediately frozen in liquid nitrogen. White matter multiple sclerosis tissue samples were selected as previously described (Alvarez et al., 2011). All patients and controls, or their next of kin, had given informed consent for autopsy and use of their brain tissue for research purposes. Ethic approval was given prior to autopsy (CHUM ethic approval: SL05.022 and SL05.023 and BH07.001).

Statistical analysis

Statistical data analysis was performed with Prism software version 6.0 g (GraphPad Software). For comparisons of two groups, two-tailed Student’s t-test was used. Comparisons of multiple groups were made using one-way or 2-way ANOVA, as described in the figure legends. Analysis of EAE clinical scores was corrected for repeated measures, and also subjected to linear regression analysis (95% confidence interval) for the analysis of the treatment effect on disease progression. Data represent mean ± standard error of the mean (SEM). *P < 0.05 was considered significant.

Results

Nasal anti-CD3 monoclonal antibody ameliorates disease in a progressive model of EAE

To study the therapeutic effect of nasal anti-CD3 in a model of progressive CNS inflammation, we investigated the course of EAE in NOD mice that develop a form of EAE that resembles progressive multiple sclerosis (Basso et al., 2008; Farez et al., 2009; Mayo et al., 2014). In this model, NOD mice immunized with a myelin oligodendrocyte glycoprotein peptide (MOG35-55) develop a self-limited acute neurological syndrome (acute phase) followed by a phase of irreversible progressive neurological impairment (progressive phase). We immunized NOD mice with MOG35-55, and initiated treatment at the onset of the progressive phase (Day 30 after immunization). We found that daily nasal administration of CD3-specific mAb (1 µg/mice) suppressed disease progression in terms of clinical score, motor performance, demyelination, axonal integrity and lesion load as compared to mice treated with an isotype control antibody, at the experimental endpoint (Day 70) (Fig. 1A–G). Anti-CD3 mAb administration also restored blood–brain barrier integrity as demonstrated by reduced extravasation of endogenous fibrin and antibody to the spinal cord (Fig. 1H). To further investigate this finding, we administered the Evans blue tracer dye intraperitoneally and FITC-conjugated dextran intravenously to measure ongoing blood–brain barrier integrity, as described (Alvarez et al., 2011). We found no extravasation of Evans blue or FITC-conjugated dextran (Figs. 1I and J) demonstrating that nasal anti-CD3 administration limits blood–brain barrier disruption resulting from the inflammatory response. Similar results were obtained when we administered nasal anti-CD3 mAb after progression was well established (Day 45 after immunization), which may represent a more clinically relevant therapeutic time for treatment, and found rapid reversal of clinical progression (Fig. 1K). To determine whether nasal anti-CD3 reached the CNS we analysed the distribution of near-infrared fluorescence labelled anti-CD3 mAb administrated nasally using an in vivo imaging system and found that the antibody accumulated in the cervical lymph nodes, but was not detected in the CNS (Supplementary Fig. 1A). Of note, neither microglia nor astrocytes express the CD3 chain, and they are not stained by anti-CD3 mAb (Supplementary Fig. 1B and C). Nasal anti-CD3 mAb did not impair the ability to clear bacterial infection in the lung (Supplementary Fig. 1D–F). We then studied the effects of nasal anti-CD3 mAb in acute EAE and similarly found that daily administration ameliorated disease progression in the later stages of EAE; it did not affect disease onset (Supplementary Fig. 2A). Taken together, these data demonstrate an ameliorating effect of nasal anti-CD3 mAb administration on progressive stages of EAE.

Nasal anti-CD3 monoclonal antibody induces an IL-10+LAP+ T cell that attenuates progressive EAE in an IL-10-dependent manner

We have previously shown that regulatory T cells induced by the nasal administration of anti-CD3 express IL-10 (Wu et al., 2008, 2009, 2010, 2011). Thus we asked whether nasal anti-CD3 mAb induces IL-10 producing T cells during the progressive phase of EAE in the NOD model. In the spleen, we found increased IL-10 secretion following both MOG and anti-CD3 agonist mAb restimulation, and increased IL-10 expression by the T cells after stimulation with PMA/ionomycin (Fig. 2A and B). Of note, we did not observe upregulation of signature cytokines or transcription factors associated with other CD4+ T-cell subsets known to secrete IL-10 including FOXP3+ Tregs (regulatory T cells) and Th2 cells (Supplementary Fig. 2B and C, and Fig. 2G). We did find that nasal anti-CD3 mAb induced the expression of latency-associated peptide (LAP) (Supplementary Fig. 2D and E), a plasma membrane protein associated with regulatory T cell lineages, and that many of the induced IL-10+ T cells (57.4 ± 2.7%) were...
Figure 1  Nasal anti-CD3 ameliorates disease in a progressive model of EAE. (A and B) Clinical scores of EAE in NOD mice treated nasally with CD3 specific or isotype control mAbs, administered daily (1 μg/mouse) from Day 30 after EAE induction (progressive phase) for the duration of the experiment. Representative data of eight independent experiments with n = 8 mice/group (mean and SEM), statistical analysis by two-way ANOVA and linear regression. (C–J) At the experimental endpoint (Day 70) mice Rotarod performance was evaluated (G), and (H) histopathology analysis of lumbar spinal cord serial sections from EAE NOD mice treated with anti-CD3 or isotype control as in A was performed. Sections were stained with haematoxylin and eosin (H&E), Luxol Fast blue stain or Bielschowsky's silver impregnation for analysis of 1944 | BRAIN 2016: 139; 1939–1957 L. Mayo et al. (continued)
LAP+ (Fig. 2C). Notably, we observed that many of the LAP+ T cells were MOG-specific (65.1 ± 4.9%) (Fig. 2D). We found an increase in CNS T cells in nasal anti-CD3 mAbs-treated mice (Fig. 2E and F), and these T cells had increased IL-10 expression (Fig. 2G and H).

We then asked whether the protective effects of nasal anti-CD3 mAbs were linked to LAP+ and IL-10+ T cells. To address this point, we initially analysed the suppressive function of anti-CD3 mAbs induced CD4+LAP+ T cells in vitro. We co-cultured CFSE-labelled naïve T cells (responder T cells) with CD4+LAP+ T cells isolated from anti-CD3 mAbs-treated NOD mice during the progressive phase of EAE (Day 60) (Fig. 2I). We found that the anti-CD3 mAb-induced T cells suppressed the responder T cell proliferation. We then performed adoptive transfer experiments in which isolated CD4+ T cells from anti-CD3 mAbs or isotype control-treated NOD mice during the progressive phase of EAE (Day 60) were transferred to a new cohort of NOD mice at the onset of the progressive phase (Fig. 2J). We found that the anti-CD3 mAb-treated T cells attenuated the progressive phase of NOD EAE to the same extent as anti CD3 mAb treated mice. Moreover, the effect was dependent on LAP+ T cells, as protection was reversed by depletion of LAP+ T cells prior to cell transfer (Fig. 2J). Of note, the beneficial effect of adoptive transfer of splenic CD4+ T cells from anti-CD3 mAb-treated mice declines after a week.

Next, we investigated the role of IL-10 on the therapeutic effect of nasal anti-CD3 mAbs using anti-IL-10 receptor (IL-10R) blocking antibodies. We found that the suppression by anti-CD3 mAbs induced T cells was reversed when IL-10 signalling was blocked (Fig. 2K), and moreover that the therapeutic effect of the nasal anti-CD3 was also abrogated when IL-10 signalling was blocked (Fig. 2L). Of note, blocking IL-10 signalling did not worsen the clinical course of EAE in the isotype control group, suggesting that during the normal course of EAE the low/basal expression of IL-10 lacks significant biological relevance to the disease progression.

We also found that IL10RA, which encodes for the ligand-binding subunit of the IL-10 receptor (Moore et al., 2001) is significantly upregulated during chronic CNS inflammation, both in NOD mice following EAE induction, (Supplementary Fig. 3A), and in multiple sclerosis lesions (Supplementary Fig. 3B), suggesting that treatments that target IL-10 may be of benefit. Of note, we were not able to detect IL-10 in the brain material of our cohort of patients with multiple sclerosis. Consistent with this, using proteomic and transcriptomic analysis, Steinman’s group also did not identify IL-10 expression in the CNS of patients with multiple sclerosis (Lock et al., 2002; Han et al., 2008).

Taken together, these data demonstrate that nasal anti-CD3 mAbs induces active regulation of progressive EAE, through a mechanism mediated by IL-10+LAP+ CD4+ T cells.

**Nasal anti-CD3 induces IL-10+ Tr1-like cells**

IL-10-secreting regulatory T cells could represent Tr1 cells, FOXP3 cells or be generated from a different lineage of T cells that have undergone chronic stimulation, resulting in the disappearance of effector T cell cytokines but the maintenance of IL-10 (exhausted T cells). To characterize the anti-CD3 mAbs induced IL-10 secreting Tregs, we performed microarrays on these cells and compared them to naïve T cells, FOXP3+ Tregs and IL27-induced Tr1 cells. To perform this experiment, we used mice that express GFP on the IL-10 promoter, which provided a way to sort IL-10+ T cells ex vivo. We generated F1 hybrid mice derived by breeding NOD and C57BL/6IL-10-GFP (B6NODF1IL-10:GFP). We have previously shown that NOD × C57BL/6 mice develop a chronic progressive form of EAE (Mayo et al., 2014). We first established that nasal anti-CD3 attenuates the progressive phase of EAE in B6NODF1IL-10:GFP mice (Fig. 3A). We then isolated CD3+CD4+IL-10+ cells from the cervical lymph nodes and spleen of anti-CD3 mAb treated B6NODF1IL-10:GFP mice during the progressive phase of EAE (Fig. 3B) and compared their transcriptional profile to naïve (CD3+CD4+CD62LhighCD44low) T cells using a microarray. We assessed the reproducibility of our data and conservation across biological replicates by calculating the correlations across all samples. We found a strong correlation among cell type replicates (Pearson correlation coefficient = 0.9828–0.9914), lower correlations between the naïve and anti-CD3 mAb induced cell types, and a strong correlation between anti-CD3 mAb induced cells recovered from the cervical lymph nodes or spleen (Supplementary Fig. 4 and Supplementary Table 1). Analysis of the cell
Figure 2 Nasal anti-CD3 induces an IL-10 + LAP + T- cell that attenuates progressive EAE in an IL-10 dependent manner. (A–I) NOD mice treated nasally with CD3 specific or isotype control mAbs following EAE induction as in (Fig. 1A). IL-10 secretion by splenic T cell in response to MOG35–55 (20 μg/ml) or anti-CD3 mAbs (0.2 μg/ml) stimulation was determined by enzyme-linked immunosorbent assay (A), and IL-10 and LAP expression by splenic CD4+ T cells was examined by fluorescence-activated cell sorting (FACS) (B and C). Data are representative of four independent experiments with n = 6 mice/group (mean and SEM). Statistical analysis by Student's t-test. (D) Proportion of MOG-specific T cells within LAP+ and LAP−/CD4+ splenic T cells in NOD EAE mice treated with nasal anti-CD3. Data are representative of two independent (continued)
transcriptomes revealed that 747 genes were differentially expressed (FDR < 0.2) in anti-CD3 mAb induced IL-10+ T cells versus naïve T cells (Fig. 3C). These genes were associated with multiple cellular functions including cell cycle, cytokine and chemokine activity, ATP binding and the regulation of the immune response (Fig. 3D). The strongest functional enrichment was associated with positive regulation of cell proliferation. Indeed, most of IL-10 secreting T cells isolated from anti-CD3 treated NOD were proliferating as measured by high expression of Ki-67 (57.3 ± 2.09%) or by measuring the proliferation of ex vivo restimulated CFSE-labelled cells (90.6 ± 0.01%) (Fig. 3E and F, respectively). Thus, these results suggest that nasal anti-CD3 mAb induced T cells are differentiated T cells as opposed to exhausted T cells.

We then compared the transcriptional profiles of in vitro-defined T cell lineages to nasal anti-CD3 mAb induced T cells. For these comparisons, we investigated Th0 cells, FOXP3+ Tregs, and Tr1 cells (differentiated with IL27 or IL27 and TGFβ (Apetoh et al., 2010) (Supplementary Fig. 4B)). Evaluation of the cell transcriptomes revealed strong correlations among cell type replicates and lower correlations across differing cell types (Supplementary Fig. 4C). We found that 514 genes were differentially regulated by Tr1 cells (FDR < 0.2), and 255 genes were differentially regulated (FDR < 0.2) by Tregs, as compared to Th0 cells (Supplementary Fig. 4D and E, and Supplementary Tables 2 and 3, respectively).

To investigate the relationship between anti-CD3 induced IL-10+ cells and other T cell types we used principal component analysis (PCA) (Fig. 3F and G, respectively). PC1 was associated with the variance between the in vivo and in vitro generated datasets, whereas PC2 was associated with the variance between cell lineage and function (Fig. 3F). We thus focused our analysis on PC2 and found that nasal anti-CD3-induced T cells are more closely associated with in vitro differentiated Tr1 cells than FOXP3 Tregs and that this is primarily driven by genes associated with known Tr1-linked genes such as IL10, IL21 and MAF (previously known as c-MAF) (Apetoh et al., 2010) (Fig. 3G). To determine the degree of similarity between nasal anti-CD3 induced T cells and in vitro induced Tr1 cells, we used Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) (Fig. 3H). We compared the upregulated genes from the Tr1 signature (349 genes) to those of the anti-CD3 mAb in vivo induced T cells, and found a strong enrichment for Tr1 signature genes (FDR q-value = 0.03) (Subramanian et al., 2005). These results demonstrate that nasal anti-CD3-induced T cells are Tr1-like. In agreement with these findings, adoptive transfer of in vitro differentiated IL-10+ Tr1 cells at the onset of the progressive phase of B6NODF1 EAE, resulted in suppression of EAE, mirroring the therapeutic effects of the IL-10+ LAP+ T cells, induced by the nasal anti-CD3 administration (Fig. 3I).

Taken together, these results demonstrate that IL-10-secreting T cells, induced by nasal anti-CD3 mAb administration, resemble Tr1 cells.

**Nasal anti-CD3 monoclonal antibody attenuates the adaptive T cell response**

To evaluate the effects of nasal anti-CD3 mAb on the peripheral adaptive immune response, we measured the response of splenocytes isolated from isotype control or anti-CD3 mAb treated mice to restimulation with MOG_{35-55} or anti-CD3 mAb. We found that nasal anti-CD3 mAb compromised the peripheral adaptive response by reducing the proliferative response to ex vivo stimulation (Fig. 4A and B). Furthermore, the frequency of IL17+ T cells in the periphery was reduced following nasal anti-CD3 mAb treatment (Fig. 4C). Consistent with this, we found a reduction in the expression levels of IL17 encoding gene and the transcription factor RORgt (Il17a and Rorc) in T cells sorted from the CNS of nasal anti-CD3 mAb-treated mice (Fig. 4D). Of note, we did not observe changes in the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF; associated with pathogenic T cells) or T-bet and IFNγ (associated with the Th1 lineage) (Fig. 4D and Supplementary Fig. 1F and G).

Thus, nasal anti-CD3 mAb both reduces Th17 polarization and induces IL-10+Tr1 like cells, which is consistent with a report that Tr1 cells regulate Th17 polarization via...
Figure 3 Nasal anti-CD3 induces IL-10⁺ Tr1-like cells. (A–H) EAE was induced in IL-10-GFP F1 hybrid mice (B6NODF1IL-10:GFP) and mice were treated nasally with CD3 specific or isotype control mAbs as in Fig. 1A. (A) Nasal anti-CD3 attenuates the of progressive phase of EAE in the B6NODF1IL-10:GFP mice. Data are representative of two independent experiments with n = 8 mice/group (means and SEM). (B) GFP (IL-10) expression by CD4⁺ T cells in the spleen and cervical lymph nodes (cLN) was examined by flow cytometry. (C) Heat map depicting the differential mRNA expression profiles in naïve CD4⁺ or CD4⁺ GFP/IL-10⁺ T cells isolated from the spleen or cLNs of B6NODF1IL-10:GFP mice during the progressive phase of EAE following nasal treatment, as detected by microarray data analysis. (D) Functional enrichment analysis of the
IL-10-dependent signalling (Huber et al., 2011). Given that Th17 responses are increased in subjects with progressive multiple sclerosis (Huber et al., 2014) regulation of Th17 levels by nasal anti-CD3 mAb may contribute to its therapeutic potential for the treatment of progressive multiple sclerosis.

**Nasal anti-CD3 monoclonal antibody suppresses astrocyte activation in an IL-10-dependent manner**

Astrocytes play an important role in the response of the CNS to inflammation including maintenance of blood–brain barrier integrity, regulation of the influx of T cells and monocytes from the periphery to the CNS and modulation of microglia and oligodendrocytes within the CNS (Myer et al., 2006; Mayo et al., 2012). In addition, we have identified a crucial role for astrocytes during CNS inflammation in the progressive phase of NOD EAE (Farez et al., 2009; Mayo et al., 2014). Thus, we investigated the effects of nasal anti-CD3 mAb on astrocytes in the progressive NOD EAE model.

We isolated astrocytes from naïve mice and from isotype control or nasal anti-CD3-treated mice on Day 70 of progressive EAE and analysed their transcriptome by Nanostring nCounter arrays using a custom-made astrocyte probe set (Mayo et al., 2014) shown in (Supplementary Table 4). We identified genes that were upregulated during EAE and downregulated by nasal anti-CD3 mAb, and genes downregulated during EAE and upregulated by nasal anti-CD3 (Fig. 5A). We then validated selected genes by quantitative PCR that are known to play an important role in CNS inflammation (Fig. 5B). We found downregulation of Ccl2, which is involved in recruitment of monocytes to the CNS (Izikson et al., 2000; Mildner et al., 2009) and of Ccl5, which is important for recruitment of peripheral immune cells to the CNS. Il6 (Il6) and toll-like receptor 2 (Th2) were downregulated, both of which are pro-inflammatory genes in the CNS (Farez et al., 2009; Miranda-Hernandez and Baxter, 2013). Of note, we found upregulation of the water channel aquaporin 4 (Aqp4), which has recently been associated with astrocyte regulation of diverse processes ranging from CSF circulation, waste clearance, neuroinflammation, cell migration, and Ca²⁺ signalling (Nagelhus and Ottersen, 2013). Restoration of AQP4 following nasal anti-CD3 was also observed by immunohistochemistry (Fig. 5C). Of note, loss of AQP4 staining in chronic EAE was not secondary to loss of astrocytes, as shown by preserved GFAP staining (Fig. 5C).

As astrocytes regulate axonal myelination (Watkins et al., 2008; Mayo et al., 2012) we also studied the expression levels of genes (n = 29) associated with demyelination at the chronic phase of NOD EAE (Day 70), as measured by the astrocyte Nanostring code set (Supplementary Table 5). In agreement with the demyelination and axonal damage shown in Fig. 1C–E, we detected upregulation of astrocytic genes associated with demyelination in progressive NOD EAE that was reduced following nasal anti-CD3 mAb administration (Supplementary Fig. 5). We present a composite statistical analysis of these results in Fig. 5D. We also focused on the effect of nasal anti-CD3 mAb on the role of astrocytes on regulating blood–brain barrier integrity (Argaw et al., 2012) and consistent with what we show in Fig. 1H–J, we found upregulation of astrocytic genes associated with blood–brain barrier degradation (Vegfa, Mmp3, Mmp9) that was reversed by nasal anti-CD3 mAb (Fig. 5E). Taken together, these data demonstrate that nasal anti-CD3 mAb attenuates astrocyte activation during progressive EAE.

To investigate whether IL-10 acts directly on murine astrocytes to regulate their function, we investigated the effect of IL-10 on primary astrocyte cultures. We found that IL-10 suppressed the expression of Ccl2, Ccl5, Csf2, Nos2, Mmp3 and Mmp9 following stimulation with IL1β (Fig. 5F). Two of these are primary molecules used by astrocytes to modulate to the CNS immune microenvironment: CCL2, which regulates Ly6Chi inflammatory monocytes recruitment to the CNS (Kim et al., 2014; Mayo et al., 2014) and GM-CSF (Cs2), which induces a pro-inflammatory phenotype in mononuclear phagocytes (Mayo et al., 2014).

To investigate the role of the IL-10-astrocyte axis on the in vivo effect of nasal anti-CD3 mAb, we used a strategy in which we knocked-down the expression of the ligand-binding subunit of the IL-10 receptor (Ill10ra) expression in astrocytes. We used a lentivirus-based system optimized for astrocyte-specific knock-down in vivo (Yan et al., 2012; Mayo et al., 2014), in which the expression of the
shRNA is driven by a Gfap promoter and coupled to a GFP reporter (Fig. 6A). We injected a validated shRNA-encoding lentivirus for Il10ra (shIl10ra) or a non-targeting control shRNA (shNT) intra-cerebroventricular during the progressive phase of EAE (35 days after EAE induction) and began nasal anti-CD3 mAb the next day. We confirmed that the expression of the GFP reporter was restricted to GFAP+ astrocytes (Fig. 6B) and that there was significant astrocyte-specific knock-down of Il10ra expression (Fig. 6C). As shown in Fig. 6D, knock-down of astrogial Il10ra reversed the therapeutic effects of the nasal anti-CD3. Taken together these data demonstrate the role of IL-10 in astrocytes in nasal anti-CD3 regulation of chronic EAE.

**Nasal anti-CD3 monoclonal antibody attenuates microglial activation**

Microglia play a central role in the control of CNS inflammation and the progression of EAE (Heppner et al., 2005; Ponomarev et al., 2011; Yamasaki et al., 2014). To investigate the effects of nasal anti-CD3 mAb on microglia, we isolated microglial cells from nasal anti-CD3 mAb treated...
Figure 5 Nasal anti-CD3 suppresses astrocyte activation. (A–E) Naive or EAE NOD mice treated with CD3-specific or isotype control mAbs during the chronic phase as in (Fig. 1A). (A) Heat map depicting mRNA expression, as detected by Nanostring nCounter analysis, in astrocytes isolated from naive or EAE NOD mice treated with CD3 specific or isotype control mAbs. Upper panels: Histogram presentation of normalized gene expression in each gene cluster. Representative data of three independent experiments, statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (B) Quantitative PCR analysis of Ccl2, Ccl5, Il6, Tlr2, and Aqp4 expression in astrocytes isolated from naive and EAE NOD mice treated as in A; expression is presented relative to Gapdh. Representative data of three independent experiments, statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (C) Immunohistochemistry analysis of spinal cords for aquaporin 4 (AQP4) expression, and the presence of astrocytes (GFAP) on subsequent sections. Scale bar = 50 μm. Data are representative of two independent experiments with n = 6 mice/group. (D) Relative expression (to NOD naive group) of genes associated with the control of demyelination in astrocytes isolated from EAE NOD mice treated with anti-CD3 or isotype control. Representative data of three independent experiments. Statistical analysis by Student’s t-test. (E) Quantitative PCR analysis of Mmp3, Mmp9 and Vegfα expression in astrocytes isolated from naive and EAE NOD mice treated as in A; expression is presented relative to Gapdh. Representative data of three independent experiments, statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (F) Cultured astrocytes were pre-treated for 1 h with IL-10 (100 ng/ml), or vehicle (PBS), followed by activation with IL1β (20 ng/ml) or left untreated. Quantitative PCR analysis of Ccl2, Ccl5, Csf2, Nos2, Mmp3, and Mmp9; expression is presented as fold change from untreated, relative to Gapdh. Data from five independent experiments (mean and SEM). Statistical analysis by two-way ANOVA, followed by Tukey post hoc analysis. *P < 0.05, **P < 0.01.
animals and analysed their transcriptional profile using an inflammatory NanoString code set. Nasal anti-CD3 mAb induced both downregulation and upregulation of gene expression in microglia (Fig. 7A). Several of the downregulated genes are known to be associated with microglial activation and we confirmed the downregulation of these genes ($IL1b$, $IL6$, $Nos2$, $Cd40$, and $Irf7$) by quantitative PCR (Fig. 7B). We then analysed gene expression according to their classification (Krausgruber et al., 2011; Murray and Wynn, 2011) as either ‘M1’ (pro-inflammatory) or ‘M2’ (anti-inflammatory) (Supplementary Table 6) and which are also thought to play a role in both multiple sclerosis and EAE (Murray and Wynn, 2011; Miron et al., 2013; Yamasaki et al., 2014). We found that nasal anti-CD3 modulated the microglial phenotype towards an anti-inflammatory pattern (Fig. 7C) with downregulation of M1-associated genes and upregulation of M2-associated genes. Thus, in addition to its effect on astrocytes, nasal anti-CD3 mAb has a profound effect on microglia in vivo.

To investigate whether IL-10 acts directly on microglia, we added IL-10 to primary microglial cultures activated with GM-CSF and measured the expression of genes known to play a role in microglial activation and which are associated with an inflammatory microglial phenotype. As shown in Fig. 7D, IL-10 suppressed the response of microglia to recombinant GM-CSF as measured by induction of $Il1b$, $Il6$, $Il12b$, $Cd40$, $Il23a$, and $Tnf$.

To investigate the role of the IL-10-microglial axis on the in vivo effect of nasal anti-CD3 mAb, we specifically knocked down $Il10ra$ in microglial cells in vivo. We used the backbone of the lentivirus-based system described above in Fig. 6. The promoter driving the shRNA expression was replaced with the CD11b promoter (Fig. 7E) to target the microglial cells (Ding et al., 2015). We injected a validated shRNA-encoding lentivirus for $Il10ra$ (sh$Il10ra$) or a non-targeting control shRNA (shNT) intraventricularly during the progressive phase of EAE (37 days after EAE induction) and began nasal anti-CD3 mAb treatment the next day. We confirmed that there was significant microglial-specific knock-down of $Il10ra$ expression (Fig. 7F). As shown in Fig. 7G, knockdown of microglial $Il10ra$ partially reversed the therapeutic effects of the nasal anti-CD3. These data demonstrate that IL-10 acts directly on microglia as well as on astrocytes.

**Nasal anti-CD3 monoclonal antibody decreases the recruitment of Ly6Chi monocytes to the central nervous system**

CNS-infiltrating monocytes (Ly6Chi) promote neurodegeneration and disease progression in EAE (Izikson et al., 2000; Mildner et al., 2009). As shown above, in
Figure 7 Nasal anti-CD3 attenuates microglial activation. (A–C) Naive or EAE NOD mice treated with CD3 specific or isotype control mAbs during the chronic phase as in Fig. 1A. (A) Heat map depicting mRNA expression, as detected by Nanostring nCounter analysis, in microglial cells isolated from naive or EAE NOD mice treated with CD3 specific or isotype control mAbs. Upper panels: Histogram presentation of normalized gene expression in each gene cluster. Representative data of three independent experiments, statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (B) Quantitative PCR analysis of Il1b, Il6, Nos2, Cd40, and Ifr7 expression in microglial cells isolated from naive and EAE NOD mice treated as in A; expression is presented relative to Gapdh. Representative data of three independent experiments, statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (C) Mean normalized expression of genes associated with M1 or M2 phenotype in microglia (Supplementary Table 6). Statistical analysis by Student’s t-test. (D) Primary microglia were pretreated for 1 h with IL-10 (100 ng/ml), or vehicle (PBS), followed by activation with GM-CSF (25 ng/ml) or left untreated. Quantitative PCR analysis of Il1b, Il6, Il12b, Cd40, H2aa, and Tnf; expression is presented as fold-change from untreated relative to Gapdh. Data from three independent experiments (mean and SEM). Statistical analysis by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. (E–G) Microglial IL-10 receptor role in mediating the therapeutic effect of nasal anti-CD3. (E) Schematic map of the microglia-specific shRNA lentiviral vector. (F and G) Intracerebroventricular injection of microglia-specific shIl10ra lentivirus ameliorates disease severity. NOD mice were injected i.c.v. with 10^7 IU of shControl, or shIl10ra lentivirus (LV, black arrow), at Day 37 after EAE induction (progressive phase). n = 10 mice per group. (F) Il10ra expression levels were determined by quantitative PCR in microglia isolated from naive or EAE NOD mice; expression normalized to Gapdh and presented relative to that of cells from naive mice. Representative data of two independent experiments. Statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. (G) EAE clinical scores. Representative data of two independent experiments. Statistical analysis by two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
association with reduced expression of Ccl2 on astrocytes (Fig. 5B), we found that nasal anti-CD3 mAb reduced the infiltration of mononuclear cells to CNS as measured by haematoxylin and eosin staining during the chronic phase on NOD EAE (Fig. 1C). We thus investigated the effect of nasal anti-CD3 mAb on recruitment of inflammatory monocytes (CD11b+Ly6Chigh and CD11b+CD45high cells) to the CNS, at the same experimental end point. As shown Fig. 8A, we found significant reduction in both the percent-ages and the total numbers of inflammatory monocytes in the CNS. Of note, no effect on the chemotaxis of mono-cytes towards CCL2 was observed when monocytes were treated with IL-10 (Supplementary Fig. 6A). However, monocyte migration towards astrocyte-conditioned media was attenuated when astrocytes were pretreated with IL-10 (Supplementary Fig. 6B). Taken together, these data suggest that the anti-CD3 mAb regulation of monocytes recruitment is secondary to the regulation of the astrocyte activation.

In situ reprogramming of inflammatory monocytes has been suggested to regulate CNS inflammation (Mayo et al., 2014; Dal-Secco et al., 2015). To determine whether nasal anti-CD3 mAb affected the phenotype of monocytes recruited to the CNS, we isolated CD11b+Ly6Chigh monocytes from nasal anti-CD3 mAb-treated mice and analysed their transcriptional profile by NanoString nCounter. We found that nasal anti-CD3 mAb significantly altered the monocyte transcriptome (Fig. 8B) by skewing

---

**Figure 8 Nasal anti-CD3 decreases the recruitment of Ly6Chi monocytes to the CNS and modulates their phenotype.** (A) Recruitment of inflammatory monocytes (defined either as CD11b+Ly6Chigh or CD11b+CD45high cells) to the CNS NOD EAE mice, treated with CD3 specific or isotype control mAbs during the chronic phase as in Fig. 1A, was analysed by flow cytometry and presented as cell frequency, and total cell numbers. Representative data of three independent experiments. Statistical analysis by Student’s t-test. (B) Volcano plot depicting changes in mRNA expression in CD11b+Ly6Chigh monocytes isolated from the CNS of NOD EAE mice (as in A), as detected by Nanostring nCounter analysis. Changes in gene expression (at least 2-fold) are indicted by colour (Red = increased expression; blue = reduced expression). Representative data of two independent experiments. (C) Mean normalized expression of genes associated with M1- or M2-phenotype in microglia (Supplementary Table 6). Statistical analysis by Student’s t-test. *P < 0.05, **P < 0.01.
CD11b⁺Ly6C<sup>hi</sup> monocytes towards a M2 anti-inflammatory phenotype (Fig. SC). Thus, nasal anti-CD3 mAb both reduces the recruitment of monocytes to CNS and modulates their immune phenotype.

**Discussion**

Secondary progressive multiple sclerosis is characterized by continuous and irreversible accumulation of neurological disability (Compston and Coles, 2008; Lassmann et al., 2012) for which there is no effective treatment. The transition to secondary progressive multiple sclerosis has been linked to a change in the nature of CNS inflammation and is thought to be mainly driven by the local innate immune response (Weiner, 2008; Lassmann et al., 2012), which may in turn be associated with abnormalities in the Tr1 cells and changes in the levels of IL-10 (Astier et al., 2007; Kleinewefeld and Hafler, 2014).

EAE models have been used to study potential treatments for multiple sclerosis. C57BL/6 mice immunized with MOG<sub>35-55</sub> peptide develop a monophasic disease whereas NOD mice develop a self-limited acute phase followed by an irreversible progressive phase that resembles secondary progressive multiple sclerosis (Basso et al., 2008; Farez et al., 2009; Mayo et al., 2014). The NOD model provides the opportunity to investigate chronic ongoing inflammation and degeneration in the CNS, although, like the acute EAE model there are differences pathologically between the NOD model and the pathological changes observed in subjects with multiple sclerosis.

We found that nasal anti-CD3 mAb induced IL-10⁺LAP⁺ regulatory T cells that resemble in vitro differentiated Tr1 cells, and suppress progressive EAE in the NOD mouse in an IL-10-dependent manner. Nasal induced-Tr1 cells attenuated the activity of both the adaptive immune response (Th17 cells) and the CNS innate cells—microglia, infiltrating monocytes, and astrocytes.

We have previously reported that oral anti-CD3 suppresses acute EAE (Ochi et al., 2006). The mechanism of oral versus nasal anti-CD3 are different as oral anti-CD3 induces TGF-beta secreting cells whereas nasal anti-CD3 induces IL-10 secreting cells. When we directly compared oral versus nasal anti-CD3 in the chronic NOD model we found that oral anti-CD3 did not affect progressive EAE in the NOD mouse (Supplementary Fig. 7), consistent with our present observations that IL-10 is the key mediator of the effects we observed with nasal anti-CD3.

Th17 cells are pro-inflammatory T cells that produce interleukin-17A (IL17A), which is considered a key mediator of chronic tissue inflammation (Baeten and Kuchroo, 2013). Although secondary progressive multiple sclerosis is considered to be primarily driven by the local innate system, IL17 has been associated with progressive multiple sclerosis and elevated levels of IL17-inducible chemokines were found in patients with secondary progressive multiple sclerosis (Baeten and Kuchroo, 2013; Huber et al., 2014). We found that nasal anti-CD3 mAb reduced Th17 polarization, consistent with reports that Tr1 cells regulate Th17 polarization via IL-10 dependent signalling (Huber et al., 2011). Astrocytes have multiple roles in CNS development and function (Seifert et al., 2006; Tsai et al., 2012; Clarke and Barres, 2013; Mayo et al., 2014), and during CNS inflammation may play different roles affecting blood–brain barrier integrity, axonal growth, monocyte recruitment and the inflammatory milieu of the CNS. We have recently identified a detrimental role for astrocytes during chronic CNS inflammation (Mayo et al., 2014), suggesting that regulating astrocyte activation may be important for the therapy of secondary progressive multiple sclerosis. We found that nasal anti-CD3 mAb attenuated the pro-inflammatory phenotype of astrocytes resulting in the downregulation of genes associated with demyelination, blood–brain barrier degradation (Vegfa, Mmp3, Mmp9), monocyte recruitment (Cc2), and microglial regulation (Csf2). Many of these changes could be attributed to the direct regulation by IL-10 of astrocyte activation. Moreover, we demonstrated that knock-down of the astrocytic IL-10 receptor subunit alpha (Il10ra), reversed the therapeutic effects of nasal anti-CD3 mAb, suggesting that in progressive EAE, astrocytes represent a main node in the regulation of the inflammatory cascade.

Microglia and CNS-infiltrating inflammatory monocytes (Ly6C<sup>hi</sup>CCR2⁺) are major components of the immune response in the CNS with profound effects on neurodegeneration (Farez et al., 2009; Mildner et al., 2009; Mayo et al., 2012; Miron et al., 2013; Yamasaki et al., 2014). They may acquire different inflammatory phenotypes that have been associated with pro- or anti-inflammatory activities. Pro-inflammatory microglia and monocytes are thought to contribute to the pathogenesis of multiple sclerosis and other CNS disorders (David and Kroner, 2011; Murray and Wynn, 2011). We found that nasal anti-CD3 mAb skewed the microglial and monocyte inflammatory phenotype towards an anti-inflammatory one. We also demonstrated that nasal anti-CD3 mAb attenuated the recruitment of inflammatory monocytes to the CNS, although exogenous IL-10 did not affect monocyte migration toward a CCL2 gradient (the chemokine that governs monocyte recruitment to the CNS in EAE) (Izikson et al., 2000; Mildner et al., 2009) (Supplementary Fig. 5). However, in line with recent studies demonstrating a role for astrocytic-CCL2 production in regulating monocyte recruitment (Kim et al., 2014; Mayo et al., 2014), we found that astrocyte-dependent monocyte migration and CCL2 production are regulated by IL-10. These results suggest that the regulation of monocyte recruitment is secondary to the regulation of astrocyte activation.

A major challenge for the treatment of inflammatory disease is how to induce regulatory T cells in a fashion that is non-toxic and translatable to the clinic setting. Parenteral anti-CD3 mAb is an approved therapy for the treatment of allograft rejection and has been investigated as a treatment for type 1 diabetes (Daifotis et al., 2013). To further study the safety profile of nasal anti-CD3 treatment, we analysed...
the in vivo distribution of the anti-CD3 mAb and the effect of nasal anti-CD3 on the lung immune system and its response to microbial infection. We found that anti-CD3 mAb accumulated in vivo in the cervical lymph nodes in line with our previous findings that the in vivo induction of Tr1 cells by nasal anti-CD3 mAb occurs in the cervical lymph nodes (Wu et al., 2011). Anti-CD3 mAb was not detected in the brain following nasal administration and did not affect the ability of the lung to clear a bacterial infection. Furthermore, nasal anti-CD3 primarily induced MOG-specific Tr1-cells. Should nasal anti-CD3 be tried in human multiple sclerosis, it is likely to have a more benign safety profile than other immunomodulatory treatments as it is triggering a physiologic pathway that has not been targeted before in multiple sclerosis and is stimulating the mucosal immune system rather than disrupting global immune pathways.

In summary, our findings identify nasal anti-CD3 mAb as a therapeutic approach to induce Tr1 type regulatory cells for the treatment of progressive forms of multiple sclerosis and potentially other types of chronic CNS inflammation.

Funding

This work was supported by NIH grants R01AI043458 and P01NS076410 to H.L.W. L.M. is supported by a postdoctoral fellowship (FG1941A1/2) and F.J.Q. is the recipient of a Harry Weaver Award both from the National Multiple Sclerosis Society. Neuropathological studies were in part funded by the Austrian Science Foundation (FWF, Project P 27744-B24).

Supplementary material

Supplementary material is available at Brain online.

References


